Neuroblastoma Stage 4 Cancer (Symptoms & Survival Rate Tool)

Age: ${document.getElementById('age').value || 'Not provided'} years

Gender: ${document.querySelector('input[name="gender"]:checked') ? document.querySelector('input[name="gender"]:checked').nextElementSibling.textContent : 'Not provided'}

Height: ${document.getElementById('height').value || 'Not provided'} ${document.querySelector('.unit-toggle .active').textContent}

Weight: ${document.getElementById('weight').value || 'Not provided'} ${document.querySelectorAll('.unit-toggle')[1].querySelector('.active').textContent}

`; document.getElementById('report-patient-info').innerHTML = patientInfo; const assessment = `

Histology: ${document.getElementById('histology').value}

MYCN Status: ${document.getElementById('mycn').value}

DNA Ploidy: ${document.getElementById('ploidy').value}

11q Status: ${document.getElementById('chromosome').value}

LDH: ${document.getElementById('ldh').value || 'Not provided'} U/L

Ferritin: ${document.getElementById('ferritin').value || 'Not provided'} ng/mL

`; document.getElementById('report-assessment').innerHTML = assessment; const riskValue = document.getElementById('risk-value').textContent; const riskCategory = document.getElementById('risk-category').textContent; const riskColor = document.getElementById('risk-category').style.color; const riskAnalysis = `

Interpretation: This risk assessment indicates a ${riskCategory.toLowerCase()} category for Neuroblastoma Stage 4 progression. This suggests a ${riskValue} probability of 5-year survival based on the provided clinical factors.

`; document.getElementById('report-risk').innerHTML = riskAnalysis; const recommendations = `

• Immediate consultation with pediatric oncology specialist
• Consideration for high-dose chemotherapy with stem cell rescue
• Immunotherapy (anti-GD2 antibodies) as maintenance therapy
• Radiation therapy for residual disease
• Comprehensive supportive care including pain management
• Genetic counseling for family members
• Regular imaging and biomarker monitoring

Disclaimer: This report provides informational support only and does not replace professional medical advice. Results are based on statistical models and may not reflect individual outcomes. Consult a qualified healthcare provider for diagnosis and treatment decisions.

`; document.getElementById('report-recommendations').innerHTML = recommendations; // Generate PDF setTimeout(() => { const { jsPDF } = window.jspdf; const doc = new jsPDF('p', 'mm', 'a4'); // Capture HTML content const element = document.getElementById('pdf-template'); html2canvas(element, { scale: 2, useCORS: true }).then(canvas => { const imgData = canvas.toDataURL('image/png'); const imgWidth = doc.internal.pageSize.getWidth(); const imgHeight = canvas.height * imgWidth / canvas.width; doc.addImage(imgData, 'PNG', 0, 0, imgWidth, imgHeight); doc.save('neuroblastoma-risk-assessment.pdf'); }); }, 500); } // Social Sharing document.querySelectorAll('.social-icon').forEach(icon => { icon.addEventListener('click', function(e) { e.preventDefault(); alert('Sharing functionality would be implemented in a production environment'); }); });

Try More Free Tools:

• Try our Cancer Survival Rate Calculator (By Type & Age)
• Try our Leukemia Risk Calculator (Lymphoma Risk App)
• Try our IMDC Kidney Cancer Risk Calculator (Renal Cancer Risk)

Free Neuroblastoma Stage 4 Risk Calculator – Survival Rate & Prognosis Assessment

• ✓ Advanced pediatric cancer originating from nerve tissue
• ✓ Most common in children under age 5
• ✓ Stage 4 indicates metastatic spread
• ✓ Prognosis depends on biological/molecular factors
• ✓ Our calculator assesses personalized survival probability

Understanding Neuroblastoma: The Basics

Neuroblastoma is a malignant tumor that develops from immature nerve cells (neuroblasts), primarily affecting infants and young children. Accounting for 6% of childhood cancers, it typically arises in adrenal glands but can occur anywhere along the sympathetic nervous system chain. Stage 4 represents the most advanced form with distant metastasis.

Key Characteristics:

• The most common cancer in infants
• Spontaneous regression in rare cases
• Heterogeneous biological behavior
• MYCN oncogene amplification in 20-25% of cases

Stage 4 Neuroblastoma: Definition and Classification

Stage 4 neuroblastoma indicates dissemination beyond the primary site to:

• Distant lymph nodes
• Bone marrow (>10% involvement)
• Bones
• Liver
• Skin
• Other organs

The International Neuroblastoma Staging System (INSS) classifies Stage 4 as:

• Any primary tumor with dissemination to distant sites
• Age >18 months with metastatic spread
• Special category: Stage 4S (infants <12 months with limited metastasis)

Symptoms and Clinical Presentation

Primary Tumor Symptoms:

• Abdominal mass or swelling
• Bone pain and limping
• Proptosis (bulging eyes) and periorbital ecchymosis
• Horner’s syndrome (drooping eyelid, pupil constriction)

Metastatic Symptoms:

Site	Symptoms
Bone	Pain, limping, fractures
Bone Marrow	Anemia, bruising, fatigue
Liver	Enlargement, abdominal distension
Skin	Blueberry muffin lesions
Spine	Weakness, paralysis

Systemic Symptoms:

• Unexplained fever
• Weight loss
• Hypertension
• Opsoclonus-myoclonus syndrome (“dancing eyes, dancing feet”)

Diagnostic Procedures and Staging Workup

Essential Diagnostic Tests:

1. Imaging Studies:
   • CT/MRI of primary site
   • MIBG scintigraphy (90% sensitivity)
   • Bone scan
   • PET-CT
2. Laboratory Tests:
   • Urinary catecholamines (VMA/HVA)
   • Serum LDH and ferritin
   • Neuron-specific enolase (NSE)
3. Histopathological Confirmation:
   • Tumor biopsy with Shimada classification
   • Bone marrow aspiration/biopsy

Molecular Diagnostics:

• MYCN amplification status (FISH)
• DNA ploidy analysis
• Chromosome 1p/11q deletion testing
• ALK mutation screening

Prognostic Factors in Stage 4 Neuroblastoma

Critical Biological Markers:

• MYCN Amplification: Reduces 5-year survival to 30-40%
• DNA Ploidy: Hyperdiploidy is favorable in infants
• Histopathology: Undifferentiated tumors have a worse prognosis
• Chromosome 11q: Aberrations predict poor outcomes

Clinical Risk Stratification:

Risk Group	Age	MYCN	Ploidy	Histology	5-Yr Survival
Low	<18mo	Non-amp	Hyperdiploid	Favorable	>95%
Intermediate	<18mo	Non-amp	–	Unfavorable	80-90%
High	>18mo	Amplified	Diploid	Unfavorable	40-60%

Treatment Approaches and Protocols

Multimodal Treatment Strategy:

Current Treatment Options:

1. Induction Chemotherapy:
   • COJEC Protocol (cisplatin, vincristine, carboplatin, etoposide, cyclophosphamide)
   • 4-6 cycles to achieve remission
2. Surgical Resection:
   • Goal: >90% tumor removal
   • Delayed after chemotherapy shrinkage
3. Myeloablative Therapy:
   • High-dose chemotherapy (busulfan/melphalan)
   • Autologous stem cell rescue
4. Radiation Therapy:
   • Primary site (21 Gy)
   • Metastatic sites with symptoms
5. Immunotherapy:
   • Anti-GD2 antibodies (dinutuximab)
   • IL-2/GM-CSF combination
   • 6-month maintenance phase
6. Differentiating Agents:
   • 13-cis-retinoic acid (isotretinoin)

Emerging Therapies:

• ALK inhibitors (lorlatinib)
• I-131 MIBG targeted radiotherapy
• CAR T-cell therapy targeting GD2
• VEGF inhibitors

Neuroblastoma Risk Assessment Calculator Explained

What Our Calculator Assesses:

• Tumor biology markers (MYCN, ploidy, histology)
• Age at diagnosis
• Metastatic burden
• Laboratory values (LDH, ferritin)
• Response to initial treatment

How It Works:

1. Input clinical parameters
2. The algorithm weights prognostic factors
3. Calculates risk category and survival probability
4. Generates a personalized report

Key Output Metrics:

• Risk stratification (low/intermediate/high)
• 5-year survival probability
• Color-coded visual risk meter
• Treatment response predictions

Interpreting Your Results:

• Low Risk (Green): >90% survival with standard therapy
• Intermediate Risk (Yellow): 70-90% survival with intensive therapy
• High Risk (Red): 40-60% survival with multimodal treatment

Supportive Care and Rehabilitation

Nutritional Management:

• High-calorie, high-protein diet
• Enteral feeding support during treatment
• Micronutrient supplementation

Pain Control Strategies:

• WHO analgesic ladder adaptation
• Nerve blocks for localized pain
• Palliative radiation for bone metastases

Long-term Survivorship Care:

Prevention and Early Detection

Genetic Counseling Indications:

• Familial neuroblastoma history
• PHOX2B or ALK germline mutations
• Hirschsprung disease association
• Congenital central hypoventilation syndrome

Surveillance Recommendations:

• Monthly abdominal palpation in infants
• Urinary VMA/HVA screening in high-risk families
• Ultrasound for abdominal masses
• Developmental milestone monitoring

Conclusion and Future Directions

Stage 4 neuroblastoma remains challenging, but treatment advances continue improving outcomes. Our risk assessment tool provides personalized prognostic information to guide treatment decisions. Ongoing research focuses on targeted therapies and immunotherapy combinations to overcome treatment resistance.

Disclaimer: This calculator provides informational support only and does not replace professional medical advice. Results are based on statistical models and may not reflect individual outcomes.

Frequently Asked Questions (FAQs) –